RNAC
Cartesian Therapeutics, Inc. NASDAQ$6.22
Mkt Cap $161.6M
52w Low $5.60
6.2% of range
52w High $15.57
50d MA $6.88
200d MA $8.46
P/E (TTM)
-1.2x
EV/EBITDA
-0.9x
P/B
—
Debt/Equity
-0.1x
ROE
103.2%
P/FCF
-2.4x
RSI (14)
—
ATR (14)
—
Beta
0.56
50d MA
$6.88
200d MA
$8.46
Avg Volume
198.0K
About
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.84 | -1.46 | -73.8% | 6.22 | -0.3% | +0.0% | — | — | — | — | — | — |
| Mar 9, 2026 | AMC | -0.82 | -1.38 | -68.3% | 9.02 | +0.9% | -5.2% | -8.4% | -10.0% | -18.1% | -18.7% | -31.8% | — |
| Nov 6, 2025 | AMC | -0.81 | -1.38 | -70.4% | 7.55 | -0.9% | +4.2% | -4.1% | -3.3% | +0.4% | -4.2% | -11.0% | — |
| Aug 7, 2025 | AMC | -0.76 | 0.50 | +165.8% | 10.54 | -0.3% | -0.1% | +5.3% | +7.5% | +11.1% | +8.4% | -3.3% | — |
| May 8, 2025 | AMC | -0.61 | -0.68 | -11.5% | 10.42 | -0.4% | -5.0% | +0.2% | -2.1% | -4.2% | +0.1% | +4.1% | — |
| Mar 20, 2025 | AMC | -0.78 | -0.59 | +24.4% | 15.93 | +2.8% | +0.8% | +0.1% | -0.1% | -6.6% | -9.9% | -35.1% | — |
| Nov 7, 2024 | AMC | -0.78 | -0.69 | +11.5% | 20.78 | +1.6% | -0.1% | -4.8% | -18.5% | -17.6% | -18.1% | +17.6% | — |
| Aug 8, 2024 | AMC | -1.07 | 0.54 | +150.5% | 12.87 | +0.3% | +3.9% | -1.3% | +6.2% | +1.6% | +12.3% | +1.9% | — |
| May 8, 2024 | AMC | -0.81 | -1.97 | -143.2% | 23.25 | -2.2% | -6.0% | -8.9% | -7.7% | +6.5% | +14.6% | +57.3% | — |
| Mar 7, 2024 | AMC | -0.30 | -2.40 | -700.0% | 19.31 | +2.0% | -0.6% | -0.7% | -8.6% | -14.6% | -16.8% | -32.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Wedbush | Maintains | Outperform → Outperform | — | $6.22 | $6.20 | -0.3% | +0.0% | — | — | — | — |
| Mar 10 | Wedbush | Maintains | Outperform → Outperform | — | $9.02 | $9.10 | +0.9% | -5.2% | -8.4% | -10.0% | -18.1% | -18.7% |
| Mar 9 | Needham | Maintains | Buy → Buy | — | $6.85 | $6.55 | -4.4% | +31.7% | +24.8% | +20.6% | +18.5% | +7.9% |
| Mar 9 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $6.85 | $6.55 | -4.4% | +31.7% | +24.8% | +20.6% | +18.5% | +7.9% |
| Jan 9 | Needham | Maintains | Buy → Buy | — | $8.12 | $8.07 | -0.6% | +1.0% | -10.5% | -5.7% | -5.9% | -9.4% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.62 | $7.55 | -0.9% | -6.2% | -6.2% | -5.0% | -2.5% | -3.9% |
| Nov 14 | BTIG | Maintains | Buy → Buy | — | $7.23 | $7.50 | +3.7% | +3.2% | +2.1% | +5.4% | -1.1% | -1.1% |
| May 8 | Needham | Maintains | Buy → Buy | — | $10.15 | $10.26 | +1.1% | +2.7% | -2.5% | +2.9% | +0.5% | -1.7% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $9.52 | $9.34 | -1.9% | +19.3% | +8.8% | +12.1% | +36.6% | +25.7% |
| Apr 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.52 | $9.34 | -1.9% | +19.3% | +8.8% | +12.1% | +36.6% | +25.7% |
Recent Filings
8-K
Cartesian Therapeutics, Inc. -- 8-K Filing
Cartesian Therapeutics reported Q1 2026 results and highlighted Descartes-08 as a promising late-stage cell therapy candidate with potential to address unmet autoimmune disease treatment needs through durable response.
Apr 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
RNAC's executive change signals potential strategic shifts and management uncertainty that could impact operational direction and investor confidence in near-term performance.
Mar 30
8-K
Cartesian Therapeutics, Inc. -- 8-K Filing
Cartesian Therapeutics (RNAC) expects 2026 to be transformative as it advances its Descartes-08 cell therapy candidate across multiple autoimmune disease indications in late-stage clinical development.
Mar 9
Data updated apr 26, 2026 11:12pm
· Source: massive.com